Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) have been given an average recommendation of “Moderate Buy” by the seven analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $8.60.

Several equities research analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Gossamer Bio in a research note on Thursday, January 22nd. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Gossamer Bio in a research report on Thursday, January 22nd. Barclays assumed coverage on Gossamer Bio in a research report on Tuesday, January 27th. They set an “overweight” rating and a $9.00 price target for the company. Finally, Wall Street Zen lowered Gossamer Bio from a “hold” rating to a “sell” rating in a report on Friday, January 23rd.

Gossamer Bio Price Performance

GOSS stock opened at $2.26 on Friday. The firm has a market cap of $523.10 million, a price-to-earnings ratio of -3.28 and a beta of 1.93. Gossamer Bio has a 1-year low of $0.76 and a 1-year high of $3.87. The firm has a fifty day moving average price of $2.96 and a two-hundred day moving average price of $2.66.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 354.50%.The company had revenue of $13.29 million for the quarter, compared to analyst estimates of $6.32 million. As a group, analysts expect that Gossamer Bio will post -0.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Gossamer Bio

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Gossamer Bio by 5.2% during the 3rd quarter. Vanguard Group Inc. now owns 12,009,773 shares of the company’s stock valued at $31,586,000 after purchasing an additional 598,981 shares in the last quarter. Acadian Asset Management LLC lifted its stake in Gossamer Bio by 12.4% during the second quarter. Acadian Asset Management LLC now owns 7,146,022 shares of the company’s stock valued at $8,786,000 after purchasing an additional 787,909 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Gossamer Bio by 100.4% during the second quarter. Geode Capital Management LLC now owns 4,555,080 shares of the company’s stock worth $5,604,000 after buying an additional 2,282,632 shares in the last quarter. Corient Private Wealth LLC grew its position in Gossamer Bio by 8.9% in the second quarter. Corient Private Wealth LLC now owns 3,693,683 shares of the company’s stock worth $4,543,000 after buying an additional 302,200 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Gossamer Bio by 629.3% in the third quarter. Millennium Management LLC now owns 3,619,329 shares of the company’s stock valued at $9,519,000 after buying an additional 3,123,081 shares in the last quarter. 81.23% of the stock is currently owned by institutional investors and hedge funds.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.